U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07140939) titled 'A Phase 3 Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat' on Aug. 21.
Brief Summary: A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Subcutaneous Fat
Intervention:
DRUG: CBL-514 Injection
Provided as a ready for use injectable CBL-514 solution
OTHER: 0.9% Sodium Chloride
Injectable 0.9% Sodium Chloride solution as placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Caliway Biopha...